Genenta Science S.p.A. - GNTA Revenue Dynamics YoY (Last Twelve Months)

The stability of Genenta Science S.p.A. (GNTA) development is ensured by the protection of US and EU medical regulations. On GURU.Markets, the annual sales growth rate (trailing 12 months) contains 0.00, which represents the latest level value. Success is based on the authority of European management and reporting transparency. The foundation consists of sophisticated laboratories and exclusive rights to viral vectors, which create a high barrier to entry for competitors.
Genenta Science (GNTA) - metric breakdowns and financial figures

For the long-term investor, Genenta Science (GNTA) represents a high-risk asset with an uncertain payback period. This metric measures the percentage change in total revenue over the last twelve months relative to the same period last year. By analyzing the LTM gross revenue dynamics, one can assess the stability of commercial flows. Given the early-stage nature of gene therapy research, the absence of proprietary revenue renders this indicator secondary. Current volatility confirms the business's total dependence on external financing.